Overview of Japanese encephalitis disease and its prevention. Focus on IC51 vaccine (Ixiaro®)


Japanese encephalitis disease
Japanese encephalitis virus
IC51 vaccine (Ixiaro®)
travel medicine


Japanese encephalitis is a vector-borne disease caused by the Japanese encephalitis virus (JEV). JEV is transmitted by mosquitoes to a wide range of vertebrate hosts, including birds and mammals. Domestic animals, especially pigs, are generally implicated as reservoirs of the virus, while humans are not part of the natural transmission cycle and cannot pass the virus to other hosts.

Although JEV infection is very common in endemic areas (many countries in Asia), less than 1% of people affected develop clinical disease, and severe disease affects about 1 case per 250 JEV infections. Although rare, severe disease can be devastating; among the 30,000-50,000 global cases per year, approximately 20-30% of patients die and 30-50% of survivors develop significant neurological sequelae.

JE is a significant public health problem for residents in endemic areas and may constitute a substantial risk for travelers to these areas. The epidemiology of JE and its risk to travelers have changed, and continue to evolve. The rapid economic growth of Asian countries has led to a surge in both inbound and outbound travel, making Asia the second most-visited region in the world after Europe, with 279 million international travelers in 2015. The top destination is China, followed by Thailand, Hong Kong, Malaysia and Japan, and the number of travelers is forecast to reach 535 million by 2030 (+4.9% per year).

Because of the lack of treatment and the infeasibility of eliminating the vector, vaccination is recognized as the most efficacious means of preventing JE.

The IC51 vaccine (Ixiaro®) is a purified, inactivated, whole virus vaccine against JE. It is safe, well tolerated, efficacious and can be administered to children, adults and the elderly. The vaccination schedule involves administering 2 doses four weeks apart. For adults, a rapid schedule (0-7 days) is available, which could greatly enhance the feasibility of its use.

Healthcare workers should inform both short- and long-term travelers of the risk of JE in each period of the year and recommend vaccination. Indeed, it has been shown that short-term travelers are also at risk, not only in rural environments, but also in cities and coastal towns, especially in tourist localities where excursions to country areas are organized.



Solomon T, Ni H, Beasley DW, Ekkelenkamp M, Cardosa MJ, Barrett AD. Origin and evolution of Japanese encephalitis virus in southeast Asia. J Virol. 2003;77(5):3091-8.

Hills S, Rabe I, Fischer M, Japanese Encephalitis, CDC Yellow Book, 2016. Available at: https://wwwnc.cdc.gov/travel/yellowbook/2018/infectious-diseases-related-to-travel/japanese-encephalitis. [Accessed on 10 October 2017].

WHO Report. Japanese Encephalitis Vaccines: WHO position paper, February 2015- Recommendations Vaccines. 2016; 34:302-303.

Schiøler KL, Samuel M, Wai KL. Vaccines for preventing Japanese encephalitis. Cochrane Database Syst Rev. 2007;(3):CD004263.

Connor B, Bunn WB. The changing epidemiology of Japanese encephalitis and New data: the implications for New recommendations for Japanese encephalitis vaccine. Trop Dis Travel Med Vaccines. 2017;3:14.

Longbottom J, Browne AJ, Pigott DM, Sinka ME, Golding N, Hay SI, Moyes CL, Shearer FM. Mapping the spatial distribution of the Japanese encephalitis vector, Culex tritaeniorhynchus Giles, 1901 (Diptera: Culicidae) within areas of Japanese encephalitis risk. Parasit Vectors. 2017;10(1):148.

Cheng V, Sridhar S, Wong S, Wong S. C. Y, Chan J. F. V, Yip C, Chau C, Au T.W.K, Hwang Y, Yau C, Lo J, Lee C, Yuen K, Japanese Encephalitis Virus Transmitted Via Blood Transfusion, Hong Kong, China. Emerging Infectious Diseases, 2018, Vol. 24, No. 1.

Campbell GL, Hills SL, Fischer M, Jacobson JA, Hoke CH, Hombach JM, Marfin AA, Solomon T, Tsai TF, Tsu VD, Ginsburg AS. Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Organ. 2011;89(10):766-74, 774A-774E.

Heffelfinger JD, Li X, Batmunkh N, Grabovac V, Diorditsa S, Liyanage JB, Pattamadilok S, Bahl S, Vannice KS, Hyde TB, Chu SY, Fox KK, Hills SL, Marfin AA. Japanese Encephalitis Surveillance and Immunization - Asia and Western Pacific Regions, 2016. MMWR Morb Mortal Wkly Rep. 2017;66(22):579-583.

Watt G, Jongsakul K. Acute undifferentiated fever caused by infection with Japanese encephalitis virus. Am J Trop Med Hyg. 2003;68:704-6.

Griffiths MJ, Turtle L, Solomon, T. Japanese encephalitis virus infection. Handb Clin Neurol. 2014;123:561-76.

Kumar R, Tripathi P, Singh S, Bannerji G. Clinical features in children hospitalized during the 2005 epidemic of Japanese encephalitis in Uttar Pradesh, India. Clin Infect Dis. 2006;43:123-31.

Burke DS, Nisalak A, Ussery MA, Laorakpongse T, Chantavibul S]. Kinetics of IgM and IgG responses to Japanese encephalitis virus in human serum and cerebrospinal fluid. J Infect Dis. 1985;151:1093-9.

Halstead SB, Jacobson J. Japanese Encephalitis Vaccines. In: Plotkin SA, Orenstein WA, Offit P, editors, Vaccines. Fourth edition: Philadelphia: Saunders Elsevier, 2008.

Halstead SB, Thomas SJ. Japanese encephalitis: new options for active immunization. Clin Infect Dis. 2010;50(8):1155-64.

Steffen R, Behrens RH, Hill DR, Greenaway C, Leder K. Vaccine-preventable travel health risks: what is the evidence--what are the gaps? J Travel Med. 2015;22(1):1-12.

Buhl MR, Lindquist L, Japanese encephalitis in travelers: review of cases and seasonal risk. J Travel Med 2009; 16: 217-219.

Halstead SB, Jacobson J, Dubischar-Kastner K. Japanese encephalitis vaccines. In: Plotkin S, Orenstein W, Offit P (eds). Vaccines, 6th edn. Amsterdam, the Netherlands: Elsevier, 2012, pp. 201-5.

Lindquist L. Recent and historical trends in the epidemiology of Japanese encephalitis and its implication for risk assessment in travellers. J Travel Med. 2018 May 1;25(suppl_1):S3-S9.

Hills S, Griggs A, Fischer M. Japanese encephalitis in travelers from non-endemic countries, 1973-2008. Am. J. Trop. Med.Hyg, 2010;82(5):930-936.

Kollaritsch H, Paulke-Korinek M, Dubischar-Kastner K. IC51 Japanese encephalitis vaccine. Expert Opin Biol Ther. 2009;9(7):921-31.

Huang GKL., Tio SY, Caly L, Nicholson S, Thevarajan I, Papadakis G, Catton M, Tong SYC, Druce J. Prolonged Detection of Japanese Encephalitis Virus in Urine and Whole Blood in a Returned Short-term Traveler. Open Forum Infectious Diseases. 2017; 4(4): ofx203. http://doi.org/10.1093/ofid

World Tourism Organization and Global Tourism Economy Research Centre (2016), UNWTO/GTERC Annual Report on Tourism Trends – 2016 Edition, Executive Summary, UNWTO, Madrid.

Pavli A, Maltezou HC. Travel-acquired Japanese encephalitis and vaccination considerations. J Infect Dev Ctries. 2015;9(9):917-24.

Halstead SB, Thomas SJ. New Japanese encephalitis vaccines: alternatives to production in mouse brain. Expert Rev Vaccines. 2011;10(3):355-64.

Wilder-Smith A, Halstead SB. Japanese encephalitis: update on vaccines and vaccine recommendations. Curr Opin Infect Dis. 2010; 23: 426-431.

Eckels KH, Yu YX, Dubois DR, Marchette NJ, Trent DW, Johnson AJ. Japanese encephalitis virus live-attenuated vaccine, Chinese strain SA14-14-2; adaptation to primary canine kidney cell cultures and preparation of a vaccine for human use. Vaccine. 1988;6(6):513-8.

Lyons A, Kanesa-thasan N, Kuschner RA, Eckels KH, Putnak R, Sun W, Burge R, Towle AC, Wilson P, Tauber E, Vaughn DW. A Phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis. Vaccine. 2007;25(17):3445-53.

Tauber E, Kollaritsch H, Korinek M, Rendi-Wagner P, Jilma B, Firbas C, Schranz S, Jong E, Klingler A, Dewasthaly S, Klade CS. Safety and immunogenicity of a Vero cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet. 2007;370(9602):1847-53.

Tauber E, Kollaritsch H, von Sonnenburg F, Lademann M, Jilma B, Firbas C, Jelinek T, Beckett C, Knobloch J, McBride WJ, Schuller E, Kaltenböck A, Sun W, Lyons A. Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine. J Infect Dis. 2008 Aug 15;198(4):493-9. doi: 10.1086/590116. Erratum in: J Infect Dis. 2010;201(8):1278.

Schuller E, Jilma B, Voicu V, Golor G, Kollaritsch H, Kaltenböck A, Klade C, Tauber E. Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 Six and 12 month results of a multicenter follow-up phase 3 study. Vaccine. 2008;26(34):4382-6.

Schuller E, Klade CS, Wölfl G, Kaltenböck A, Dewasthaly S, Tauber E. Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: a randomized, observer-blind, controlled Phase 3 study. Vaccine. 2009;27(15):2188-93.

CDC. Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2010;59(No. RR-1).

Schuller E, Klingler A, Dubischar-Kastner K, Dewasthaly S, Müller Z. Safety profile of the Vero cell-derived Japanese encephalitis virus (JEV) vaccine IXIARO(®). Vaccine. 2011;29(47):8669-76.

Kaltenböck A, Dubischar-Kastner K, Eder G, Jilg W, Klade C, Kollaritsch H, Paulke-Korinek M, von Sonnenburg F, Spruth M, Tauber E, Wiedermann U, Schuller E. Safety and immunogenicity of concomitant vaccination with the cell culture-based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX1440 in healthy subjects: A single-blind, randomized, controlled Phase 3 study. Vaccine. 2009;27(33):4483-9.

Dubischar-Kastner K, Eder S, Buerger V, Gartner-Woelfl G, Kaltenboeck A, Schuller E, Tauber E, Klade C. Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO, IC51. Vaccine. 2010;28(32):5197-202.

Eder S, Dubischar-Kastner K, Firbas C, Jelinek T, Jilma B, Kaltenboeck A, Knappik M, Kollaritsch H, Kundi M, Paulke-Korinek M, Schuller E, Klade CS. Long-term immunity following a booster dose of the inactivated Japanese Encephalitis vaccine IXIARO®, IC51. Vaccine. 2011 Mar 21;29(14):2607-12. doi: 10.1016/j.vaccine.2011.01.058.

Kaltenböck A, Dubischar-Kastner K, Schuller E, Datla M, Klade CS, Kishore TS. Immunogenicity and safety of IXIARO (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age. Vaccine. 2010;28(3):834-9.

Jelinek T, Cromer MA, Cramer JP, Mills DJ, Lessans K, Gherardin AW, Barnett ED, Hagmann SHF, Askling HH, Kiermayr S, Kadlecek V, Eder-Lingelbach S, Taucher C, Dubischar KL. Safety and immunogenicity of an inactivated Vero cell-derived Japanese encephalitis vaccine (IXIARO(®), JESPECT(®)) in a pediatric population in JE non-endemic countries: An uncontrolled, open-label phase 3 study. Travel Med Infect Dis. 2018. pii: S1477-8939(18)30046-2. doi: 10.1016/j.tmaid.2018.03.003*

Dubischar KL, Kadlecek V, Sablan B Jr, Borja-Tabora CF, Gatchalian S, Eder-Lingelbach S, Mueller Z, Westritschnig K. Safety of the Inactivated Japanese Encephalitis Virus Vaccine IXIARO in Children: An Open-label, Randomized, Active-controlled, Phase 3 Study. Pediatr Infect Dis J. 2017;36(9):889-897.

Dubischar KL, Kadlecek V, Sablan JB, Borja-Tabora CF, Gatchalian S, Eder-Lingelbach S, Kiermayr S, Spruth M, Westritschnig K. Immunogenicity of the Inactivated Japanese Encephalitis Virus Vaccine IXIARO in Children From a Japanese Encephalitis Virus-endemic Region. Pediatr Infect Dis J. 2017 Sep;36(9):898-904.

Centers for Disease Control and Prevention (CDC). Use of Japanese encephalitis vaccine in children: recommendations of the advisory committee on immunization practices, 2013. MMWR Morb Mortal Wkly Rep. 2013 Nov 15;62(45):898-900.

European Medicine Agency (EMA). EMA/18321/2013 EMEA/H/C/963 Available at: http://www.eespof.gr/sites/default/files/EPAR_IXIARO_ENG.pdf [Accessed on 10 March 2018].

Cramer JP, Dubischar K, Eder S, Burchard GD, Jelinek T, Jilma B, Kollaritsch H, Reisinger E, Westritschnig K. Immunogenicity and safety of the inactivated Japanese encephalitis vaccine IXIARO® in elderly subjects: Open-label, uncontrolled, multi-center, phase 4 study. Vaccine. 2016 Aug 31;34(38):4579-4585.

Gurav YK, Bondre VP, Tandale BV, Damle RG, Mallick S, Ghosh US, Nag SS. A large outbreak of Japanese encephalitis predominantly among adults in northern region of West Bengal, India. J Med Virol. 2016;88(11):2004-11.

Lawrence J. Japanese encephalitis outbreak in India and Nepal. Euro Surveill. 2005;10(9):E050922.4

Dhimal M, Ahrens B, Kuch U. Climate Change and Spatiotemporal Distributions of Vector-Borne Diseases in Nepal – A Systematic Synthesis of Literature. PLoS One. 2015; 10(6): e0129869.http://dx.doi.org/10.1371/journal.pone.0129869. [Accessed 8 March 2017].

Zhang F, Liu Z, Zhang C, Jiang B. Short-term effects of floods on Japanese encephalitis in Nanchong, China, 2007-2012: A time-stratified case-crossover study. Sci Total Environ. 2016 Sep 1;563-564:1105-10. doi: 10.1016/j.scitotenv.2016.05.162.

Centers for Disease Control and Prevention (CDC). Japanese encephalitis in two children--United States, Morbidity Mortality Weekly Report. 2011; 60(9):276-8.https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6009a3.htm [Accessed 10 March 2017].